CCL19

Across TCGA pan-cancer cohorts, CCL19 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCL19 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CCL19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCL19 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CCL19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	1.000	0.572	.013	7	view →
HNSC	DFS	Quartile	III,IV	0.562	0.836	.024	4	view →
LUAD	DFS	Median	II,III,IV	0.620	0.997	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCL19–LSCC (DFS)

Open the LSCC breakdown →